Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Gastroenterology | Oncology | Radiology | Anesthesiology & Pain | Journal

Back to Journal Articles

Stereotactic Radiotherapy Treats Colorectal Liver Mets

Last Updated: August 25, 2011.

 

Strong association between local control and overall survival even for heavily pretreated patients

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Stereotactic body radiotherapy is a safe and effective treatment for colorectal liver metastases, with a strong association between local control and overall survival even for heavily pretreated patients, according to a study published in the September 1 Cancer.

THURSDAY, Aug. 25 (HealthDay News) -- Stereotactic body radiotherapy is a safe and effective treatment for colorectal liver metastases, with a strong association between local control and overall survival even for heavily pretreated patients, according to a study published in the September 1 Cancer.

Daniel T. Chang, M.D., from Stanford University in California, and colleagues investigated the outcomes of stereotactic body radiotherapy in patients with colorectal liver metastases. A total of 65 patients with 102 lesions treated from August 2002 to May 2009 were included (median follow-up 1.2 years). Patients with one to four lesions were given one to six fractions of stereotactic body radiotherapy (median dose 42 gray [Gy]) and radiologic imaging for three or more months posttreatment. The three-fraction dose required for more than 90 percent local control was estimated using a tumor control probability (TCP) model after converting the schedule into a biologically equivalent dose (BED), single-fraction equivalent dose, or linear quadratic model-based single-fraction dose.

The investigators found that before stereotactic body radiotherapy, 47 (72 percent) and 27 (42 percent) patients had one or more, and two or more chemotherapy regimens, respectively. A significant association was observed between total dose, dose/fraction and BED with local control by lesion on separate evaluation by multivariate analysis. Nonactive extra hepatic disease was correlated with overall survival on multivariate analysis and sustained local control was closely associated. The estimated dose range needed for more than 90 percent local control for one year was 46 to 52 Gy in three fractions.

"Liver stereotactic body radiotherapy is well tolerated and effective for colorectal liver metastases," the authors write.

One of the study authors disclosed a financial relationship with Bayer.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2011 HealthDay. All rights reserved.


Previous: S-Nitrosylation of Toxins Prevents Clostridium Infection Next: Occipital Padding Maintains Neutral Spine Alignment

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.